Lumizyme

Active Ingredient(s): Alglucosidase Alfa
FDA Approved: * May 24, 2010
Pharm Company: * GENZYME
Category: Enzymes

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Lumizyme Overview

Alglucosidase alfa (Lumizyme, Myozyme, Genzyme) is an enzyme replacement therapy (ERT) orphan drug for treatment of Pompe disease (Glycogen storage disease type II), a rare lysosomal storage disorder (LSD).[3] Chemically speaking, the drug is an analog of the enzyme that is deficient in patients affected by Pompe disease, alpha-glucosidase. It is the first drug available to treat this disease.[1] Contents 1 Status 2 Side effects 3 References 4 External link...

Read more Lumizyme Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Alglucosidase_alfa

Recent Lumizyme Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

NDC Database Records for Lumizyme: (1 result)

Sorted by National Drug Code

• 58468-0160 Lumizyme 5 mg/ml Intravenous Injection, Powder, for Solution by Genzyme Corporation

Other drugs which contain Alglucosidase Alfa or a similar ingredient: (2 results)

• ALGLUCOSIDASE ALFA
• MYOZYME Alglucosidase Alfa